

Omega-3 Fatty Acid Compounds Position Statement

Prescribers should review all patients prescribed omega-3 in line with North Central London guidance ([link](#))

Omacor® (omega-3 fatty acid) is recommended to reduce the risk of pancreatitis, as adjunct to dietary modifications, for patients who meet all the following criteria:

- **inherited hypertriglyceridaemia (type 3 hyperlipidaemia, lipoprotein lipase deficiency, or in presence of raised chylomicrons and VLDL)**
- **fasting TG remains >10mmol/L**
- **taking maximum tolerated fibrate and statin**
- **under the care of a lipid specialist**

Omega-3 fatty acids are non-formulary for all other indications and should not be initiated in primary or secondary care.

NHS England category: item of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns

Groups / Individuals who have overseen the development of this guidance:	Joint Formulary Support
Groups which were consulted and have given approval:	NCL Joint Formulary Committee
File name:	2_Omega-3_position.pdf
Version number:	2.0
Available on:	www.ncl-mon.nhs.uk
Disseminated to:	All Trusts and CCGs in NCL
Equality impact assessment:	Low
NCL Joint Formulary Committee Approval date:	March 2019
Review date:	March 2022